Moderna Inc MRNA

$223.37 -7.98 (-3.45%)

Valuation

Market cap
93,609,072,000
Revenue TTM
$1,944,000,000
Net income TTM
$-2,822,000,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-145.16%
Debt to equity
0.09

Trading

Volume
8,072,000
Avg volume
15,780,092
Day's range
$221.70 – $231.35
Shares out
404,621,000
Stochastic %K
5%
Beta
1.16
Analysts
Hold
Price target
$151.67

Price

Company profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public...

Show more

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 714 6500
Website
https://www.modernatx.com
Address
325 Binney Street, Cambridge, United States

Latest news

Stocktwits

The_BlueWave Nov 14, 11:26 AM
$MRNA Back to 50 soon
0 replies
DrBurton Nov 14, 6:56 AM
$MRNA $MRNA target 6 hit
0 replies
Rphrush Nov 14, 2:52 AM 1 replies
DoinkTheClownExplains Nov 14, 2:38 AM
$FITZ imagine paying Keith $1200+ a year for his OBA membership to get recommendations for stocks like $RCAT and $LTBR , but then he misses $MRNA . I would not be a happy member. HOOYAH! Which btw is just Jim Cramer’s BOOYAH with an H. And Keith’s must have name, Suze Orman had must have documents for years. 🙄
0 replies
55X_ROI_Q1_2026 Nov 14, 1:44 AM
$SLS $MRNA The Power of Positive Phase 3 Trial Results. MRNA at $22 earlier in the year, was bumping around $35 to $40 in the days before its before releaseing its P3 Cancer Vaccine Results. - Topline Results were announced and the Share Price Jumped to $160 Range in a Day. and the share price continued to climb up to a High of $280 --- adding over $80B $80 Billion in market value - based on Phase 3 trial results. -- P3 Registrational Results are A License to Print Money - that the market Must and Will Reconcile in the equity. Something very Similar is about to Happen Here. $XBI
1 replies
None_ Nov 14, 12:52 AM
$MRNA $MRK Moderna readies commercial cancer vaccine production ahead of FDA filing https://endpoints.news/moderna-readies-commercial-cancer-vaccine-production-ahead-of-fda-filing/
0 replies
Arroyoym Nov 14, 12:32 AM
$MRNA people getting killed with Margin are trimming winners. This is the first window the clown shorts have had and it’s due to macro conditions, upcoming catalysts before the INT FDA decision • Late 2026: pivotal mRNA-3927 rare-disease data • Dec. 12: early multiple myeloma data at ASH • Year-end target: INT + Keytruda melanoma filing after Phase 3 showed a 42% lower risk of recurrence or death vs. Keytruda alone Biggest near-term swing: mRNA-3927 data. Biggest INT milestone: FDA filing acceptance and a decision date. H2 2027 is an estimate.
1 replies
X001 Nov 14, 12:02 AM
$MRNA Hope you all sold, pitty to be a bag holder for the next 5 years...
0 replies